Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 3Lymphoma, Follicular 2Lymphoma, B-Cell 2Smoldering Multiple Myeloma 1Recurrence 1Meningeal Carcinomatosis 1Lymphoma 1Hodgkin Disease 1Disease Progression 1Burkitt Lymphoma 1

Interventions

Lenalidomide 3Bortezomib 3Dexamethasone 2vandetanib 1umbralisib 1ublituximab 1marizomib 1durvalumab 1carotuximab 1avelumab 1Zoledronic Acid 1Vitamin D 1Transplantation, Autologous 1Tamoxifen 1Standard of Care 1Practice Guidelines as Topic 1Palliative Care 1Oxaliplatin 1Melphalan 1Leucovorin 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Folfox protocol 1Fluorouracil 1Filgrastim 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Disease Progression × Transplantation, Autologous × Clear all
NCT02043847 2024-11-13

BMT-03

University of Illinois at Chicago

Phase 1 Completed
12 enrolled 12 charts
Plasma cell

Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡